Lys125

Site Information
ktEWLDGkHVVFGkV SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 466190
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	immunoprecipitation ( 1 , 3 ) , mass spectrometry ( 2 , 4 , 5 , 6 , 7 , 8 , 9 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 ) , mass spectrometry (in vitro) ( 1 ) , modification-specific antibody ( 1 ) , mutation of modification site ( 3 ) , western blotting ( 1 , 3 )
Disease tissue studied:	colorectal cancer ( 19 , 20 ) , colorectal carcinoma ( 19 , 20 ) , gastric cancer ( 7 ) , leukemia ( 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 ) , chronic myelogenous leukemia ( 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 ) , lung cancer ( 2 ) , non-small cell lung cancer ( 6 , 8 , 9 ) , non-small cell lung adenocarcinoma ( 2 , 6 ) , non-small cell squamous cell lung carcinoma ( 9 )
Relevant cell line - cell type - tissue:	'muscle, smooth'-'heart, artery' ( 1 ) , A549 (pulmonary) ( 2 , 21 ) , HCC78 (pulmonary) ( 52 , 60 ) , HCT116 (intestinal) ( 19 , 20 , 54 , 55 ) , HCT15 (intestinal) ( 65 , 66 ) , HCT8/S11 (intestinal) ( 67 ) , HeLa (cervical) ( 4 ) , HeLa S3 (cervical) ( 56 ) , HT-29 (intestinal) ( 58 , 59 ) , Jurkat (T lymphocyte) ( 5 , 21 , 40 , 41 , 43 , 44 ) , K562 (erythroid) ( 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 ) , KMS-18 (B lymphocyte) ( 25 , 26 ) , MKN-45 (gastric) ( 7 ) , MV4-11 (macrophage) ( 21 , 42 , 46 , 47 ) , NCI-H1703 (squamous) ( 9 ) , NCI-H2228 (pulmonary) ( 6 ) , NCI-H3255 (pulmonary) ( 8 ) , NCI-H716 (intestinal) ( 63 , 64 ) , OCI-ly3 (B lymphocyte) ( 33 , 35 , 38 , 39 ) , platelet-blood ( 1 ) , RC-K8 (B lymphocyte) ( 34 , 36 , 37 ) , Reh (B lymphocyte) ( 27 , 28 , 29 ) , SEM (B lymphocyte) ( 30 , 31 , 32 ) , SNU-C2B (intestinal) ( 57 ) , SW48 (intestinal) ( 61 , 62 ) , SW620 (intestinal) ( 45 , 50 , 51 , 53 ) , VSMC ('muscle, smooth') ( 3 )

Upstream Regulation
Treatments:	angiotensin_2 ( 3 ) , thrombin ( 1 )

Downstream Regulation
Effects of modification on biological processes:	cell adhesion, induced ( 3 ) , exocytosis, induced ( 3 ) , signaling pathway regulation ( 3 )

References
1	Rosa A, et al. (2022) Cyclophilin A Is Not Acetylated at Lysine-82 and Lysine-125 in Resting and Stimulated Platelets. Int J Mol Sci 23 35163387 Curated Info
2	Wu Q, et al. (2015) Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line. Sci Rep 5, 9520 25825284 Curated Info
3	Soe NN, et al. (2014) Acetylation of cyclophilin A is required for its secretion and vascular cell activation. Cardiovasc Res 101, 444-53 24293519 Curated Info
4	Weinert BT, et al. (2013) Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. Cell Rep 4, 842-51 23954790 Curated Info
5	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
6	Rikova K (2013) CST Curation Set: 18854; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
7	Rikova K (2012) CST Curation Set: 16030; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
8	Rikova K (2012) CST Curation Set: 16031; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
9	Rikova K (2012) CST Curation Set: 16032; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
10	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
11	Moritz A (2010) CST Curation Set: 9922; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
12	Moritz A (2010) CST Curation Set: 9919; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
13	Moritz A (2010) CST Curation Set: 9921; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
14	Moritz A (2010) CST Curation Set: 9920; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
15	Moritz A (2010) CST Curation Set: 9818; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
16	Moritz A (2010) CST Curation Set: 9817; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
17	Moritz A (2010) CST Curation Set: 9820; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
18	Moritz A (2010) CST Curation Set: 9819; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
19	Moritz A (2010) CST Curation Set: 9796; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
20	Moritz A (2010) CST Curation Set: 9797; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
21	Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40 19608861 Curated Info
22	Cherry J (2007) CST Curation Set: 2726; Year: 2007; Biosample/Treatment: cell line, KMS-12-BM/DMSO; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
23	Cherry J (2007) CST Curation Set: 2730; Year: 2007; Biosample/Treatment: cell line, KMS-12-BM/SAHA 3h; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
24	Cherry J (2007) CST Curation Set: 2731; Year: 2007; Biosample/Treatment: cell line, KMS-12-BM/SAHA 6h; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
25	Cherry J (2007) CST Curation Set: 2727; Year: 2007; Biosample/Treatment: cell line, KMS-18/DMSO; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
26	Cherry J (2007) CST Curation Set: 2729; Year: 2007; Biosample/Treatment: cell line, KMS-18/SAHA 6h; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
27	Cherry J (2007) CST Curation Set: 2707; Year: 2007; Biosample/Treatment: cell line, Reh/DMSO; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
28	Cherry J (2007) CST Curation Set: 2708; Year: 2007; Biosample/Treatment: cell line, Reh/SAHA 3h; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
29	Cherry J (2007) CST Curation Set: 2709; Year: 2007; Biosample/Treatment: cell line, Reh/SAHA 6h; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
30	Cherry J (2007) CST Curation Set: 2710; Year: 2007; Biosample/Treatment: cell line, SEM/DMSO; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
31	Cherry J (2007) CST Curation Set: 2711; Year: 2007; Biosample/Treatment: cell line, SEM/SAHA 3h; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
32	Cherry J (2007) CST Curation Set: 2712; Year: 2007; Biosample/Treatment: cell line, SEM/SAHA 6h; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
33	Cherry J (2007) CST Curation Set: 2510; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/DMSO; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
34	Cherry J (2007) CST Curation Set: 2436; Year: 2007; Biosample/Treatment: cell line, RC-K8/DMSO; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
35	Cherry J (2007) CST Curation Set: 2437; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/DMSO; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
36	Cherry J (2007) CST Curation Set: 2438; Year: 2007; Biosample/Treatment: cell line, RC-K8/SAHA 3h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
37	Cherry J (2007) CST Curation Set: 2439; Year: 2007; Biosample/Treatment: cell line, RC-K8/SAHA 6h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
38	Cherry J (2007) CST Curation Set: 2440; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/SAHA 3h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
39	Cherry J (2007) CST Curation Set: 2441; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/SAHA 6h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
40	Possemato A (2007) CST Curation Set: 2336; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
41	Possemato A (2007) CST Curation Set: 2343; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
42	Cherry J (2007) CST Curation Set: 2314; Year: 2007; Biosample/Treatment: cell line, MV4-11/SAHA; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
43	Possemato A (2006) CST Curation Set: 2194; Year: 2006; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
44	Possemato A (2006) CST Curation Set: 2188; Year: 2006; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
45	Li Y (2006) CST Curation Set: 2115; Year: 2006; Biosample/Treatment: cell line, SW620/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
46	Cherry J (2006) CST Curation Set: 2029; Year: 2006; Biosample1/Treatment/Isotope: cell line, MV4-11/SAHA/L, Biosample2/Treatment/Isotope: cell line, MV4-11/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
47	Cherry J (2006) CST Curation Set: 2030; Year: 2006; Biosample1/Treatment/Isotope: cell line, MV4-11/SAHA/L, Biosample2/Treatment/Isotope: cell line, MV4-11/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
48	Cherry J (2006) CST Curation Set: 2034; Year: 2006; Biosample1/Treatment/Isotope: cell line, Nomo-1/SAHA/L, Biosample2/Treatment/Isotope: cell line, Nomo-1/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
49	Cherry J (2006) CST Curation Set: 2035; Year: 2006; Biosample1/Treatment/Isotope: cell line, Nomo-1/SAHA/L, Biosample2/Treatment/Isotope: cell line, Nomo-1/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
50	Li Y (2006) CST Curation Set: 1973; Year: 2006; Biosample/Treatment: cell line, SW620/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
51	Li Y (2006) CST Curation Set: 1974; Year: 2006; Biosample/Treatment: cell line, SW620/untreated &'\|\|' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
52	Guo A (2006) CST Curation Set: 1855; Year: 2006; Biosample1/Treatment/Isotope: cell line, HCC78/TSA 24h/L, Biosample2/Treatment/Isotope: cell line, HCC78/none/H; Disease: non-small cell lung cancer; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
53	Li Y (2006) CST Curation Set: 1828; Year: 2006; Biosample1/Treatment/Isotope: cell line, SW620/serum starved &'\|\|' serum starved/L, Biosample2/Treatment/Isotope: cell line, SW620/serum starved/TSA/H; Disease: colorectal carcinoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
54	Li Y (2006) CST Curation Set: 1658; Year: 2006; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
55	Li Y (2006) CST Curation Set: 1659; Year: 2006; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
56	Kim SC, et al. (2006) Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 23, 607-18 16916647 Curated Info
57	Li Y (2006) CST Curation Set: 1640; Year: 2006; Biosample/Treatment: cell line, SNU-C2B/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
58	Li Y (2006) CST Curation Set: 1632; Year: 2006; Biosample/Treatment: cell line, HT-29/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
59	Li Y (2006) CST Curation Set: 1633; Year: 2006; Biosample/Treatment: cell line, HT-29/untreated &'\|\|' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
60	Guo A (2006) CST Curation Set: 1600; Year: 2006; Biosample/Treatment: cell line, HCC78/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
61	Li Y (2006) CST Curation Set: 1564; Year: 2006; Biosample/Treatment: cell line, SW48/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
62	Li Y (2006) CST Curation Set: 1565; Year: 2006; Biosample/Treatment: cell line, SW48/untreated &'\|\|' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
63	Li Y (2006) CST Curation Set: 1566; Year: 2006; Biosample/Treatment: cell line, NCI-H716/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
64	Li Y (2006) CST Curation Set: 1567; Year: 2006; Biosample/Treatment: cell line, NCI-H716/untreated &'\|\|' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
65	Li Y (2006) CST Curation Set: 1469; Year: 2006; Biosample/Treatment: cell line, HCT15/untreated &'\|\|' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
66	Li Y (2006) CST Curation Set: 1472; Year: 2006; Biosample/Treatment: cell line, HCT15/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
67	Li Y (2006) CST Curation Set: 1475; Year: 2006; Biosample/Treatment: cell line, HCT8/S11/untreated &'\|\|' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info